Madrigal Pharmaceuticals, Inc. (MDGL)
| Market Cap | 8.25B |
| Revenue (ttm) | 515.55M |
| Net Income (ttm) | -281.90M |
| Shares Out | 22.29M |
| EPS (ttm) | -12.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 211,051 |
| Open | 360.00 |
| Previous Close | 359.00 |
| Day's Range | 357.76 - 371.79 |
| 52-Week Range | 200.63 - 377.46 |
| Beta | -1.03 |
| Analysts | Strong Buy |
| Price Target | 439.71 (+18.73%) |
| Earnings Date | Aug 5, 2025 |
About MDGL
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for MDGL stock is "Strong Buy." The 12-month stock price target is $439.71, which is an increase of 18.73% from the latest price.
News
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Confere...
Madrigal Pharmaceuticals CEO: We're positioned for decades of growth
Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their GLP-1 strategy.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Soergel - Executive VP & Chief Medical Officer Mardi C. Dier - Execu...
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term
Madrigal Pharmaceuticals, Inc.'s Rezdiffra showed strong Q1 2025 sales of $137.3M that highlight robust U.S. demand and early commercial momentum in non-cirrhotic NASH patients. Key catalysts include ...
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC...
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
CONSHOHOCKEN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
• Provides Protection Through Sept. 2044; Will Be Listed in FDA's Orange Book CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval
Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease nonci...
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care...
In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals
Madrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include pote...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Madrigal Pharmaceuticals has a first-mover advantage in the huge MASH market due to the approval of Rezdiffra just over a year ago. The initial rollout of the compound is encouraging, and the company ...
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive...
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso...
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.
Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH Dr. Taub's pioneering research in academia and industry led to the first FDA-approv...
Madrigal Appoints Jacqualyn A. Fouse, Ph.D.
Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's P...
Madrigal CEO on Q4 earnings beat, MASH drug market opportunity
Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom).